Table 1.
Baseline characteristics of the two groups
| IG | OG | Unweighted standardized mean differences | Weighted standardized mean differences | ||||
|---|---|---|---|---|---|---|---|
| N | 3919 | 683 | p | ||||
| Female (n, %) | 2639 | 67.3 | 433 | 63.4 | 0.044 | 0.08 | − 0.01 |
| Age (mean, sd) (year) | 36.1 | 10.9 | 38.9 | 11. | < 0.001 | − 0.25 | 0.01 |
| Monofocal onset (n, %) | 3750 | 95.7 | 649 | 95 | 0.434 | 0.03 | − 0.0003 |
| EDSS at baseline (median, q1–q3) | 1.5 | 1–2 | 1.5 | 1–2.5 | 0.245 | − 0.07 | 0.01 |
| Relapses in the year before treatment start (n, %) | 2763 | 70.5 | 462 | 67.6 | 0.132 | 0.06 | 0.02 |
| ARR (mean, sd)* | 1.4 | 0.6 | 1.3 | 0.7 | 0.388 | 0.04 | 0.01 |
| DD (median, q1–q3) | 66 | 23–249 | 70 | 21–277 | 0.0001 | − 0.12 | 0.01 |
*Only in patients with relapses in the last year
ARR, annualized relapse rate; EDSS, Expanded Disability Status Scale; IG, injectable group; OG, oral group; DD, disease duration